Sangamo Therapeutics ended 2024 with only enough cash to fund its operations into the first quarter of 2025, but CEO Sandy Macrae said he is confident an imminent deal for the company’s Fabry disease gene therapy candidate, isaralgagene civaparvovec (ST-920), will fund Sangamo through human proof-of-concept for its two lead wholly-owned genetic medicine programs.
Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline
New Hemophilia Partners Also Circling
Low on cash when Pfizer handed back rights to its hemophilia A gene therapy, Sangamo is talking to partners for its Fabry disease gene therapy to fund its two lead programs through proof-of-concept.
